Less than a week after a judge blocked Actavis plc from forcing patients to switch to new version of its Alzheimer’s drug Namenda, the company has brought on new legal firepower from Arnold & Porter and Wachtell, Lipton, Rosen & Katz to take the case to the U.S. Court of Appeals for the Second Circuit.
A&P’s Lisa Blatt and Wachtell’s George Conway III made their first appearance in the case on Tuesday, joining Actavis’ counsel at White & Case. The company notified U.S. District Judge Robert Sweet in Manhattan that it’s appealing his Dec. 11 decision enjoining the company from halting sales of its older twice-daily version of Namenda—a move that the judge ruled was designed to thwart generic competition. In a follow-up order on Monday, Sweet ordered Actavis and its Forest Laboratories unit to continue selling twice-daily Namenda until a patent on the drug expires and generics can enter the market in the summer of 2015.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
